Settings for recombinant adenoviral-based vaccines
AssigneeCrucell Holland B.V.
InventorsRonald Vogels, Maria Grazia Pau, Lennart Holterman, Stefan Kostense, Menzo Jans Emco Havenga, Mieke Caroline Sprangers
Life of this patent
Estimating the term…
Abstract
The present invention provides new uses of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, the invention provides new assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting.
Claims13
A method of delivering a polynucleotide of interest to a subject utilizing an adenoviral delivery vehicle, the method comprising:
- administering to the subject a recombinant adenovirus vector of Ad35 serotype having a polynucleotide encoding a malaria antigen;
- and
- administering to the subject, subsequent to administering the recombinant adenovirus vector of the Ad35 serotype, a recombinant adenovirus vector of Ad26 serotype having a polynucleotide encoding essentially the same malaria antigen.
A method of delivering a polynucleotide encoding a malaria antigen to a subject, the method comprising:
- administering a recombinant adenovirus vector of Ad26 serotype to a subject previously administered a recombinant adenovirus vector of Ad35 serotype, wherein the recombinant adenovirus vector of Ad35 serotype and the adenovirus vector of Ad26 serotype each comprise a polynucleotide encoding essentially the same malaria antigen.
A kit of parts comprising a priming composition and a boosting composition, the kit of parts comprising:
- a priming composition comprising:
- a first recombinant adenovirus vector of Ad35 serotype comprising a polynucleotide encoding a malaria antigen, and
- a pharmaceutically acceptable carrier;
- and
- a boosting composition comprising a second recombinant adenovirus vector of Ad26 serotype comprising a polynucleotide encoding a malaria antigen and a pharmaceutically acceptable carrier.
A method of delivering a polynucleotide encoding a malaria antigen to a subject, the method comprising:
- administering a recombinant adenovirus vector of Ad26 serotype to a subject previously administered a recombinant adenovirus vector of Ad35 serotype, wherein the recombinant adenoviruses each comprise a polynucleotide encoding essentially the same malaria antigen.
A method of delivering a polynucleotide encoding a malaria antigen to a human or animal, the method comprising:
- screening a human or animal for the presence of neutralizing antibodies against an adenovirus of Ad35 serotype;
- and
- administering a recombinant adenovirus vector of a Ad35 serotype encoding a malaria antigen, and subsequently with a recombinant adenovirus of Ad26 serotype encoding essentially the same malaria antigen.
A method of delivering polynucleotides encoding a malaria antigen to a subject, the method comprising:
- screening a subject for the presence of neutralizing antibodies against an adenovirus of Ad35 serotype;
- administering to the subject a recombinant adenovirus vector of Ad35 serotype comprising a first polynucleotide encoding the malaria antigen;
- and
- subsequent thereto, administering to the subject a recombinant adenovirus of Ad26 serotype comprising a second polynucleotide encoding the malaria antigen,
- so as to deliver the first and second polynucleotides encoding the malaria antigen to the subject.
A method of delivering a polynucleotide of interest to a subject utilizing an adenoviral delivery vehicle, the method comprising:
- administering to the subject a recombinant adenovirus vector of Ad26 serotype having a polynucleotide encoding a malaria antigen;
- and
- administering to the subject, subsequent to administering the recombinant adenovirus vector of Ad26 serotype, a recombinant adenovirus vector of Ad35 serotype having a polynucleotide encoding essentially the same malaria antigen.
A method of delivering a polynucleotide encoding a malaria antigen to a subject, the method comprising:
- administering a recombinant adenovirus vector of Ad35 serotype to a subject previously administered a recombinant adenovirus vector of Ad26 serotype, wherein the recombinant adenovirus vector of Ad26 serotype and the adenovirus vector of Ad35 serotype each comprise a polynucleotide encoding essentially the same malaria antigen.
A kit of parts comprising two immunological compositions, the kit of parts comprising:
- a first immunological composition comprising:
- a first recombinant adenovirus vector of Ad35 serotype comprising a polynucleotide encoding a malaria antigen, and
- a pharmaceutically acceptable carrier;
- and
- a second immunological composition comprising:
- a second recombinant adenovirus vector of Ad26 serotype comprising a polynucleotide encoding a malaria antigen, and
- a pharmaceutically acceptable carrier,
- wherein the malaria antigen in the first and second recombinant adenovirus are essentially the same.
A method of delivering a polynucleotide encoding a malaria antigen to a subject, the method comprising:
- administering a recombinant adenovirus vector of Ad35 serotype to a subject previously administered a recombinant adenovirus vector of Ad26 serotype, wherein the recombinant adenoviruses each comprise a polynucleotide encoding essentially the same malaria antigen.
Dependencies are inferred from the claim text.